Discovery Laboratories

Discovery Laboratories, Inc. is a specialty pharmaceutical company leveraging its platform technology in humanized lung surfactants to develop novel respiratory therapies and pulmonary drug delivery products. Surfactants are produced naturally in the lungs and are essential to the lungs' ability to absorb oxygen.

Our humanized surfactant technology is being developed initially for critical care patients with life-threatening respiratory disorders where there are few or no approved therapies available. Surfaxin®, our lead product, is currently in Phase 3 clinical trials for Respiratory Distress Syndrome in premature infants (RDS), a Phase 3 clinical trial for Meconium Aspiration Syndrome in full-term infants (MAS), and a Phase 2 clinical trial for Acute Lung Injury/Acute Respiratory Distress Syndrome in adults (ALI/ARDS).



We are also developing aerosolized formulations of our humanized surfactant to treat respiratory conditions such as asthma and as a novel pulmonary drug delivery vehicle to render drugs more effective when delivered to or via the respiratory tract.



A lack of functional surfactant is associated with several severe respiratory diseases. Research has established that surfactant replacement is highly effective in treating RDS and holds great promise in treating MAS, ALI/ARDS, asthma and other respiratory disorders. However, RDS is the only respiratory disease being treated today with approved surfactants, which are principally animal derived. The current supply of these surfactants is limited and their manufacture is both inexact and expensive, making it difficult to develop these products to treat broader populations for RDS therapy or other respiratory diseases.



Because our products are based on an engineered humanized surfactant, they can be produced economically at scale, as a high quality pharmaceutical, without the risk of potential transmission of animal-borne diseases or adverse immunological reaction. Products from our technology platform have the potential to be superior to currently marketed surfactants, treat critical care respiratory conditions, and treat larger, ambulatory patient populations that could benefit from surfactant therapy or drug delivery.

Contact Details: 2600 Kelly Road, Suite 100 Warrington PA 18976-3622 United States of America Tel: 215.488.9300 Fax: 215.488.9301 Email: ir@discoverylabs.com WWW: www.discoverylabs.com/

Loading...

Recent Publications by Discovery Laboratories:
Inhibition of neutrophil elastase reduces lung injury and bacterial count in hamsters. Neutrophil elastase (NE) has been recognized as a double-edge sword as it...	23rd May, 2009	Minase Research Institute, Discovery Laboratories II, Ono Pharmaceutical	Pulm Pharmacol Ther. 2008 Dec;21(6):884-91. Epub 2008 Oct 17. DOI Direct Link
Evaluation of the searching abilities of HBOP and HBSITE for binding pocket detection. We evaluated the pocket-searching abilities of the computer programs HBOP...	29th April, 2009	Discovery Laboratories, Toyama Chemical Co., Ltd., 2-4-1 Shimookui, Toyama	J Comput Chem. 2009 Dec;30(16):2728-37. DOI Direct Link
Optimizing the neonatal thermal environment. Devices used to maintain thermal stability in preterm infants have...	29th September, 2006	Discovery Laboratories, Inc, Warrington, Pennsylvania, USA.	Neonatal Netw. 2006 Jul-Aug;25(4):251-60.
Comparison of consensus scoring strategies for evaluating computational models of protein-ligand complexes. Here, the comparisons of performance of nine consensus scoring strategies,...	15th April, 2006	Discovery Laboratories, Toyama Chemical Co., Ltd., Japan.	J Chem Inf Model. 2006 Jan-Feb;46(1):380-91. DOI Direct Link
Discovery of nonpeptidic small-molecule AP-1 inhibitors: lead hopping based on a three-dimensional pharmacophore model. We designed and synthesized small-molecule activator protein-1 (AP-1)...	17th February, 2006	Discovery Laboratories, Toyama Chemical Co., Ltd., 4-1 Shimookui 2-chome,	J Med Chem. 2006 Jan 12;49(1):80-91. DOI Direct Link
→View more Discovery Laboratories research publications.

Press Releases on Discovery Laboratories:
New appointments prepare Morphochem for cancer product development	1st October, 2003	Morphochem	New appointments prepare Morphochem for cancer product development Munich, Germany, 16 October 2003…Morphochem AG, the transnational
CORRECTED - New appointments prepare Morphochem for cancer product	1st October, 2003	Morphochem	New appointments prepare Morphochem for cancer product development Munich, Germany, 16 October 2003…Morphochem AG, the transnational evolutionary drug discovery and
BioSeeker launches new report "New Targets and Drug Discovery	1st January, 1970	Bioseeker	BioSeeker launches new report "New Targets and Drug Discovery Platforms in Antifungal R&D" According to the Antifungal Work Group at NIH

BioNews Results for Discovery Laboratories:
FDA warns five Genzyme drugs could be contaminated	Biz Journals:  Nov 13 2009 6:01PM Matching: discovery laboratories
Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Succ	CNW Telbec:  Nov 13 2009 3:16PM Matching: discovery laboratories
Lilly (Eli) & Co : Dr Steven Paul Retire from ...	Investegate:  Nov 13 2009 2:35PM Matching: discovery laboratories
Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor	Red Orbit:  Nov 13 2009 4:19PM Matching: discovery laboratories
Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor	Red Orbit:  Nov 13 2009 4:19PM Matching: discovery laboratories
Promote your company here: BioNewsCast - Press Release Distribution	→View more Discovery Laboratories news.

Discovery Laboratories Clinical Trials:
Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old

Discovery Laboratories Patents:
US Patent No.	Title
7582312	Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
7541331	Surfactant treatment regimen
5962523	Methods of using butyric acid derivatives to protect against hair loss

Discovery Laboratories (DSCO) Financial information Links from Barchart
DSCO Quote from from Barchart.com
DSCO Chart from from Barchart.com
DSCO Profile from from Barchart.com
DSCO Opinion from from Barchart.com
→View more Discovery Laboratories finance information.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 12 individuals from Discovery Laboratories using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 568 times since April 2007, the link to the organisation's website has been followed 103 times

Search for more companies in Warrington

Search for more companies in PA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Discovery Laboratories